Rabeprazole (Aciphex)

A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Also Known As:

Aciphex; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; Dexrabeprazole; E 3810; E3810; LY-307640; LY307640; Pariet; Rabeprazole Sodium; LY 307640; Sodium, Rabeprazole

Networked: 517 relevant articles (125 outcomes, 159 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Higuchi, Kazuhide: 13 articles (12/2019 - 01/2003)
2.	Kinoshita, Yoshikazu: 13 articles (07/2018 - 01/2003)
3.	Kusano, Motoyasu: 12 articles (07/2018 - 12/2008)
4.	Fujimoto, Kazuma: 10 articles (01/2017 - 10/2005)
5.	Sloan, Sheldon: 10 articles (04/2014 - 06/2002)
6.	Takeuchi, Toshihisa: 9 articles (12/2019 - 07/2014)
7.	Hongo, Michio: 9 articles (01/2017 - 12/2008)
8.	Robinson, M: 8 articles (11/2003 - 05/2001)
9.	Fujiwara, Yasuhiro: 7 articles (02/2021 - 01/2003)
10.	Arakawa, Tetsuo: 7 articles (01/2017 - 01/2003)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 03/01/2002 - "In this large, open-label trial, rabeprazole rapidly and effectively relieved gastro-oesophageal reflux disease symptoms in most patients with erosive oesophagitis. " 04/01/2014 - "Rabeprazole was effective in maintaining endoscopic/histologic healing during a 24-week maintenance period in children with endoscopically proven GERD. " 01/01/2014 - "Rabeprazole was effective in reducing the symptoms of GERD; the Likert scale scores of symptoms decreased significantly for all patients from 0-4 weeks and 4-8 weeks. " 09/01/2010 - "Rabeprazole was again significantly effective in patients with positive findings for esophageal reflux (p = 0.0025). " 05/01/2008 - "The addition of rabeprazole offered significant improvement in GERD scores in both groups."
2.	Heartburn (Pyrosis) 05/01/2010 - "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs. placebo: 82.58% and 62.17% (ITT; P < 0.0001) [per protocol 86.74% rabeprazole vs. 74.93% placebo (P < 0.0254)]. " 06/01/2002 - "After a 2-wk, single-blind placebo run-in phase, patients were randomized to receive 10 mg or 20 mg of rabeprazole or placebo once daily for 4 wk. Rabeprazole rapidly and effectively relieved heartburn, with significant improvements on day 1 of dosing. " 08/01/2000 - "There were also significant differences between the two groups favoring rabeprazole with respect to resolution or improvement of heartburn symptoms and improvement in sense of well-being. " 01/01/2001 - "In nonerosive GORD, 4-week studies have shown rabeprazole to be more effective than placebo in relieving heartburn and various other gastrointestinal symptoms. " 08/01/2013 - "Heartburn relapse rates did not differ significantly between patients treated with rabeprazole 10 and 20 mg/d for 1 year (relative risk (RR) = 1.29; 95% confidence interval (CI): 0.97-1.72), but differed in patients treated for 5 years (RR = 1.274; 95% CI: 1.005-1.615). "
3.	Infections 10/01/2012 - "Repair of the abdominal wall is the last stage of abdominal surgery; pariet complications, particularly infection, can have serious impact on operative results. " 10/01/2006 - "pylori infection and treated with rabeprazole (20 mg). " 03/01/2004 - "pylori infection were enrolled to receive a 4-week course of rabeprazole treatment, and the subsequent healing rates and symptom relief were compared. " 06/01/2003 - "pylori infection with rabeprazole." 04/01/2001 - "[Pariet in current patterns of eradication of Helicobacter pylori infection]."
4.	Peptic Esophagitis (Reflux Esophagitis) 01/01/2017 - "Conclusion Twice-daily treatment with rabeprazole improved the subjective symptoms and health-related quality of life in patients with refractory reflux esophagitis more effectively than the standard once-daily dose." 04/01/2012 - "Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study." 05/01/2019 - "Furthermore, rabeprazole sodium (RS) administration, reflux esophagitis (RE), and intraoperative and postoperative complications were also evaluated. " 01/01/2017 - "Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study." 05/01/2012 - "Treatment with rabeprazole resulted in a decrease from 18.6 at baseline to 6.7 at week 8 in underweight reflux esophagitis subjects, and from 15.0 to 6.3 in underweight NERD patients. "
5.	Peptic Ulcer (Peptic Ulcers) 04/01/2005 - "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents. " 05/01/2015 - "Recurrent peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg groups. " 05/01/2015 - "The full analysis set consisted of 151 and 150 subjects in the long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. " 07/09/2009 - "Rabeprazole is a useful, well tolerated and cost-effective option for the treatment of GORD, NERD, peptic ulcer and other gastric acid-related diseases (including ZES), and provides an appropriate alternative to other currently available PPIs, with the added benefits of having a consistent efficacy profile and low drug interaction potential due to its predominantly nonenzymatic metabolism." 09/01/2006 - "A total of 112 patients with active peptic ulcer were randomized to receive either rabeprazole 10 mg q.d. "

Related Drugs and Biologics

1.	Omeprazole (Prilosec)
2.	Proton Pump Inhibitors
3.	Acids
4.	Amoxicillin (Wymox)
5.	Cytochrome P-450 CYP2C19
6.	Ranitidine (Zantac)
7.	Esomeprazole (Nexium)
8.	Famotidine (Pepcid)
9.	Clarithromycin (Biaxin)
10.	Levofloxacin (Levaquin)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Cholecystectomy
4.	Complementary Therapies (Alternative Medicine)
5.	Gastrectomy